# DP-R208 Pharmacokinetic Study

> **NCT02709187** · PHASE1 · COMPLETED · sponsor: **Alvogen Korea** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DP-R208
- **DRUG:** Candesartan cilexetil
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02709187
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709187, "DP-R208 Pharmacokinetic Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02709187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*